| May 14, 2015 | ISSUE NUMBER 401 VOL 4 |
Brand of the Year
Sovaldi and Harvoni: Pharm Exec’s Brand of the Year
Sovalda and Harvoni together have been chosen as Pharm Exec’s 9th Brand of the Year. We profile how the treatment has reversed expectations around the listless product launch and revived industry reputation for startling breakthrough innovations
...Read more
From Care to Cure
This year’s Pharm Exec Brand of the Year is a huge game-changer, but the big-picture impact will come down to pricing, distribution, and the broader goal of making sure that those patients who need the cure, get the cure, writes William Looney
...Read more
Four Perspectives That Help Build Business Advantage
How to join the elite group of life sciences companies
achieving sustained growth
 Learn more
Gilead’s Next Steps on HCV: A Four-Point Plan
In discussions with Pharm Exec, Gilead Sciences offered a single overriding goal for the hepatitis C virus (HCV) franchise over the next 18 months: to drive science that will lead to better regimens for treatment, especially for those patients who have been diagnosed
...Read more
Event
Sharks for Adherence
Attendees will scrutinize “Shark Tank” style pitches for innovative adherence ideas at this summer’s Patient Adherence and Access Summit. Casey McDonald previews the event that hopes to give the audience a good look at what’s new and innovative in the field
...Read more
Roundtable
What’s Real in Rare Disease
Pharm Exec convened an expert panel on rare disease to highlight the challenges of serving expectant patients in this uniquely complex market access environment
...Read more
Special Feature
Med Man: A Pharma Exec in 1960
Inspired by TV’s Mad Men (which reaches its finale on Sunday), Julian Upton puts himself into a 1960 executive’s shoes to describe the 'ethical pharma' industry of half a century ago
...Read more
|
|
|
 //OXiGENE (south San Francisco, CA) appointed Bill Schwieterman, M.D., as President and Chief Executive Officer. The company’s current CEO, Dai Chaplin, Ph.D., will become Chief Scientific Officer. //Xencor (Monrovia, CA) announced the appointments of Mark Lotz, R.Ph., as Vice President, Regulatory Affairs and Wayne Saville, M.D., as Vice President, Clinical Oncology. //Cambridge, MA, startup Surface Oncology hired AZ’s former Head of Oncology, Detlev Biniszkiewicz, to become its new CEO. //Versartis (Menlo Park, CA) named Jay Shepard as President and Chief Executive Officer, succeeding Jeffrey L. Cleland, PhD, who will remain as a senior scientific advisor. // |
|
|
|
|
|
